Alvotech is a prominent player in the biosimilar industry, but many other companies are also vying for a share of this rapidly growing market. Here are some of the key players to watch:
Major players:
- Amgen: A large American multinational biotechnology company that has developed and commercialized biosimilars for several high-profile drugs, including Enbrel, Humira, and Rituxan.
- Samsung Bioepis: A South Korean biopharmaceutical company that is a subsidiary of Samsung Group. It has a strong biosimilars portfolio and has partnered with several other companies to commercialize its products.
- Biogen: An American multinational biotechnology company that has developed and commercialized several biosimilars, including Rituxan and Neupogen.
- Pfizer: An American multinational pharmaceutical company that has developed and commercialized several biosimilars, including Inflectra and Eprex/Januvia.
- Merck: An American multinational pharmaceutical company that has developed and commercialized several biosimilars, including Lucentis and Renvela.
- Sandoz: A Swiss multinational pharmaceutical company that is a subsidiary of Novartis. It has a strong biosimilars portfolio and is one of the world's leading suppliers of biosimilars.
Emerging players:
- Momenta Pharmaceuticals: An American biopharmaceutical company that is developing and commercializing biosimilars for several high-profile drugs. (Momenta was recently acquired by Johnson & Johnson.)
- Fujifilm Diosynth Biologies: A Japanese biopharmaceutical company that is contract manufacturing biosimilars for several other companies.
- Celltrion Healthcare: A South Korean biopharmaceutical company that is developing and commercializing biosimilars for several high-profile drugs.
- Dr. Reddy's Laboratories: An Indian multinational pharmaceutical company that is developing and commercializing biosimilars for several high-profile drugs.
- Epirus Biopharmaceuticals: An American biopharmaceutical company that is developing biosimilars for several high-profile drugs. However, it was closed. Epirus has filed for Chapter 7 bankruptcy protection, handed its Remicade (infliximab) biosimilar to Reliance Life Sciences.
These are just a few of the many players in the biosimilar industry. The landscape is constantly evolving, and new companies are emerging all the time. As biosimilars become more widely adopted, we can expect to see even more competition in this market.
